Placebo | navafenterol 50 μg | navafenterol 200 μg | navafenterol 400 μg | navafenterol 900 μg | navafenterol 1800 μg | navafenterol 2100 μg | Overall | |
---|---|---|---|---|---|---|---|---|
N | 12 | 6 | 6 | 6 | 6 | 6 | 5 | 16 |
Any TEAE, n (%) | 7 (58.3) | 5 (83.3) | 5 (83.3) | 3 (50.0) | 3 (50.0) | 3 (50.0) | 2 (40.0) | 14 (87.5) |
Most common TEAEs, n (%)a | ||||||||
Headache | 3 (25.0) | 3 (50.0) | 1 (16.7) | 2 (33.3) | 2 (33.3) | 1 (16.7) | 0 | 10 (62.5) |
Nasopharyngitis | 1 (8.3) | 3 (50.0) | 1 (16.7) | 0 | 0 | 0 | 2 (40.0) | 7 (43.8) |
Chest discomfort | 1 (8.3) | 1 (16.7) | 1 (16.7) | 0 | 0 | 0 | 0 | 3 (18.8) |
Skin irritation | 0 | 1 (16.7) | 1 (16.7) | 0 | 0 | 1 (16.7) | 0 | 3 (18.8) |
Wheezing | 1 (8.3) | 1 (16.7) | 1 (16.7) | 0 | 0 | 0 | 0 | 3 (18.8) |
Cough | 0 | 1 (16.7) | 0 | 0 | 1 (16.7) | 0 | 0 | 2 (12.5) |
Dizziness | 1 (8.3) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 | 2 (12.5) |
Feeling hot | 0 | 1 (16.7) | 0 | 0 | 0 | 0 | 1 (20.0) | 2 (12.5) |
Nausea | 0 | 1 (16.7) | 0 | 0 | 1 (16.7) | 0 | 0 | 2 (12.5) |